Skip to content
value.today
Genprex Inc. logo

Genprex Inc.

GNPX
$3 Mmarket cap on Oct 30, 2026-80.6% since Jan 2024
Compare
World rank
#27,573
Revenue
—
For year ending December-2025
Net income
$-16 M
SEC filing
Employees
13
As of March 15, 2026
SEC filing

Genprex Inc. in brief

Genprex Inc. is a listed company in the Biotechnology industry, based in Austin, Texas, USA. Its market value was $3 M on 30 October 2026, which makes it the 27,573rd largest listed company in the world and the 4,477th largest in the USA on this site. It employs about 13 people. Its shares trade under the symbol GNPX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Genprex Inc.

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.

From the company's annual report filed with the US SEC: read the report

Genprex Inc. timeline

2 events, 2013–2017
  1. 2013
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 13 October 2017; shares registered for exchange trading on 13 October 2017.

Events of Genprex Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$29 M$58 M$87 M$117 M2023202420252026

World rank over time

▼ down 5,362 places since 2022
2022-01-07: #22218#22,21820222022-12-25: #25207#25,20720222023-07-30: #26185#26,18520232024-01-05: #30053#30,05320242026-03-08: #13142#13,14220262026-08-01: #24081#24,08120262026-10-14: #27294#27,29420262026-10-30: #27580#27,5802026

Rank in USA: #4,350 (Jan 2022) · #4,774 (Dec 2022) · #4,850 (Jul 2023) · #4,446 (Jan 2024) · #2,440 (Mar 2026) · #4,172 (Aug 2026) · #4,394 (Oct 2026) · #4,479 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.3×
Free cash flow yield
-647.8%
Net margin
—
Operating margin
—
Return on equity
-203.9%
Liabilities / assets
21.7%
Profit per employee
$-1.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-12M—FY18Fiscal year ending Dec 2019: revenue —, net income $-11M—FY19Fiscal year ending Dec 2020: revenue —, net income $-18M—FY20Fiscal year ending Dec 2021: revenue —, net income $-21M—FY21Fiscal year ending Dec 2022: revenue —, net income $-24M—FY22Fiscal year ending Dec 2023: revenue —, net income $-31M—FY23Fiscal year ending Dec 2024: revenue —, net income $-21M—FY24Fiscal year ending Dec 2025: revenue —, net income $-16M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-16M$-16M—
Dec 2024——$-21M$-21M—
Dec 2023——$-31M$-31M—
Dec 2022——$-24M$-24M—
Dec 2021——$-21M$-21M—
Dec 2020——$-18M$-18M—
Dec 2019——$-11M$-11M—
Dec 2018——$-12M$-12M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-15M————
Dec 2024$-18M————
Dec 2023$-25M————
Dec 2022$-18M$0M$-18M——
Dec 2021$-14M$0M$-14M$-0.42—
Dec 2020$-14M$0M$-14M$-0.51—
Dec 2019$-7M$0M$-7M$-0.66—
Dec 2018$-7M$0M$-7M$-0.90—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-5M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-4M—Mar ’26Three months to Jun 2026: revenue —, net income $-4M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Genprex Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-16 M
Net income
$-16 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$2 M
Total equity
$8 M

As of December-2025

Top 20 institutional investors in Genprex Inc.#

As of Sep 30, 2026
20 institutions held 6,163 shares (about 0.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.7%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 20 largest institutional investors in Genprex Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Fiduciary Trust Co3,552New0.43%$0 MNov 13, 2026
2Vanguard Capital Management LLC1,653New0.20%$0 MNov 13, 2026
3UBS Group AG443New0.05%$0 MNov 10, 2026
4Tower Research Capital LLC (TRC)260New0.03%$0 MNov 16, 2026
5Robinhood Markets, Inc.61—0.01%$0 MNov 18, 2026
6Jones Financial Companies Lllp56New0.01%$0 MNov 13, 2026
7Royal Bank Of Canada53New0.01%$0 MNov 16, 2026
8Cheviot Value Management, LLC46-954 (-95.40%)0.01%$0 MNov 9, 2026
9BlackRock, Inc.10New0.00%$0 MNov 13, 2026
10Osaic Holdings, Inc.8New0.00%$0 MNov 12, 2026
11SBI Securities Co., Ltd.8New0.00%$0 MOct 22, 2026
12Allworth Financial LP3New0.00%$0 MNov 17, 2026
13Jpmorgan Chase & Co2New0.00%$0 MNov 12, 2026
14Morgan Stanley2New0.00%$0 MNov 13, 2026
15Harbour Investments, Inc.1-107 (-99.07%)0.00%$0 MNov 9, 2026
16Group One Trading LLC1New0.00%$0 MNov 10, 2026
17Capital Advisors, Ltd. LLC1New0.00%$0 MOct 27, 2026
18Bogart Wealth, LLC1New0.00%$0 MNov 10, 2026
19Global Retirement Partners, LLC1New0.00%$0 MNov 10, 2026
20HighMark Wealth Management LLC1New0.00%$0 MNov 17, 2026

Mutual funds holding Genprex Inc.#

4 funds hold shares worth $0 M. Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Genprex Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC25,119$0 M—<0.01%+79%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.5,950$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,522$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC685$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Genprex Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$22
2 sales, 1 insider
Net, 12 months
-$22
open market only
Insiders on file
12
since
Genprex Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Brent M. LongneckerDirectorSell-8$1.230$109,157Form 4
filed Brent M. LongneckerDirectorSellindirect-10$1.230$120Form 4
filed Ryan M. ConferPresident, CEO and CFO, DirectorShares withheld for tax-9,330$2.000$19 K36,331Form 4
filed Mark Stanley BergerChief Medical OfficerShares withheld for tax-7,168$2.000$14 K21,692Form 4
filed William R. Wilson Jr.DirectorGrant or award+9,000——9,157Form 4
filed Mark Stanley BergerChief Medical OfficerGrant or award+28,500——28,860Form 4
filed Ryan M. ConferPresident, CEO and CFO, DirectorGrant or award+45,000——45,661Form 4
filed Brent M. LongneckerDirectorGrant or award+9,000——9,165Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Genprex Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
123,259
82.2% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 6.684-for-1 split

Trading halts

  • 2026-07-15 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-10-28 15:20 UTC, code LUDP, resumed 15:25 UTC
  • 2025-10-20 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 464 shares at $2.04
  • : 1,390 shares at $1.95
  • : 808 shares at $1.81
  • : 4,398 shares at $1.81
  • : 148 shares at $1.98

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Genprex Inc. scorecard#

Passes 3 of the 9 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.3×Price to book 0.3× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✓Net income higher than five years earlier-$16 M-$16 M in fiscal 2025 against -$18 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$16 MNet income -$16 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-338.8%-338.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.9×Current ratio 3.85 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Genprex Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Genprex Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue—00000—000
Research and development9.41118129.0r7.32.01.00.30.4
General and administrative6.11113r1212r118.7113.03.8
Total costs and expenses162131r2421r1811123.34.1
Operating income−16−21−31r−24−21r−18−11−12−3.3−4.1
Interest and finance income—0.10.20.10.00.00.00.00.00
Interest expense and finance costs———————0.00.00
Other non-operating income (expense)———————−0.0−0.00
Income tax00.000——————
Net income including minority interests———————−12−3.3—
Net income attributable to shareholders−16−21−31−24−21r−18−11−12−3.3−4.1
Earnings per share, basic-17.40-266.89r-22.56-19.80r-0.44r-0.51-0.66-0.90-0.29-0.38
Earnings per share, diluted————-0.42-0.51-0.66-0.90-0.29-0.38
Shares, weighted average (basic)0.90.1r1.41.2r47—————
Shares, weighted average (diluted)————473616141211
Balance sheet
Cash and cash equivalents7.81.66.72139272.08.60.21.6
Receivables——00.000.00.00.00.00.0
Other current assets0.5r0.50.80.50.50.40.20.20.00.0r
Current assets8.4r2.17.5213928r3.08.80.21.6
Property, plant and equipment000.00.00.00.00.00.00.00.0
Other intangible assets—00.80.70.60.60.50.40.30.2
Non-current assets—————————0.3
Total assets10r4.1112543313.59.31.31.9
Accounts payable0.71.11.40.41.00.20.40.30.60.3
Current liabilities2.2r2.53.32.81.60.50.50.40.80.3
Total liabilities2.2r2.5——1.6—————
Retained earnings−171−155−134−103−79r−58r−40−30−17−14
Shareholders' equity8.01.67.42241313.08.90.41.6
Total liabilities and equity10r4.1112543313.59.31.31.9
Shares outstanding0.1r0.2r1.51.2r484319151211r
Cash-flow statement
Share-based compensation0.33.35.44.75.3r4.23.55.41.32.7
Cash from operating activities−15−18r−25−18r−14−14−6.9−6.8−2.2−1.2
Capital expenditure———0−0.0r−0.0−0.0−0.0−0.0−0.0
Intangible assets bought—0−0.1−0.1−0.0r−0.1−0.1−0.1−0.1−0.1
Cash from investing activities00.8r−0.1−0.1r−0.1−2.3−0.9−0.1−0.1−0.1
Shares issued2212110.026421.3150.82.7
Cash from financing activities2212110.026421.3150.82.7
Change in cash6.2−5.1−14−181125−6.68.4−1.41.4
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Genprex Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$729 K
Other top executives, average
$689 K
the CEO earned 1.1× this
$100 invested is now
—
Genprex Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$729 K$906 K$689 K—
2024Chief executive$542 K$589 K$500 K—
2023Chief executive$1.7 M$910 K$940 K—

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Genprex Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 4 · Directors and officers 1 · Material agreement 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1

Genprex Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 5, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Genprex Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$10 MNo. 2$10 to $50 million2equity, optionsSEC
Dec 2013$1 MNo. 1Under $2 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Genprex Inc.#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $155 K a year.

Certified, FY2022
1
#2,062 among companies on value.today
Worker positions
1
Median wage offered
$155 K
a year, full-time
Applications filed
1
Genprex Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Associate Director, Formulations & Analytical DevelopmentNatural Sciences Managers1$155 K

Where: Mt Juliet, TN 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Genprex Inc.

How Genprex Inc. compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Genprex Inc.🇺🇸$3 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 15, 2026
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Genprex Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Genprex Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Genprex Inc.? Suggest a correction